#### MORGANS DAVID J JR

Form 4

January 17, 2007

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

0.5

January 31, Expires: 2005

**OMB APPROVAL** 

Estimated average

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \* MORGANS DAVID J JR

(First)

(State)

280 EAST GRAND AVENUE

(Middle)

(Zin)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

CYTOKINETICS INC [CYTK]

3. Date of Earliest Transaction

(Month/Day/Year)

01/16/2007

(Check all applicable)

Director 10% Owner \_X\_\_ Officer (give title \_ Other (specify below)

SVP-Drug Discovery and Dev

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

### **SOUTH SAN** FRANCISCO, CA 94080

(City)	(State) (2	Table	I - Non-De	erivative S	Securi	ties Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction	ransaction(A) or Disposed of		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial	
		(Month/Day/Year)	(Instr. 8)	(Instr. 3,	(A) or (D)	5) Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)	Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	01/16/2007		Code V $M_{\underline{(1)}}$	Amount 5,000	A		50,000	D	
Common Stock	01/16/2007		S(2)	5,000	D	\$ 8.31	45,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: MORGANS DAVID J JR - Form 4

# $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ame Underlying Sect (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	An or No
Incentive Stock Option (right to buy)	\$ 1.2	01/16/2007		M		5,000	07/10/2002(3)	07/10/2012	Common Stock	4
Incentive Stock Option (right to buy)	\$ 1.2						05/21/2003(4)	05/21/2013	Common Stock	5
Incentive Stock Option (right to buy)	\$ 6.5						04/08/2004(5)	03/08/2014	Common Stock	3
Incentive Stock Option (right to buy)	\$ 6.59						04/11/2005(6)	04/11/2015	Common Stock	3
Incentive Stock Option (right to buy)	\$ 7.15						03/01/2006(7)	03/01/2016	Common Stock	1
Non-Qualified Stock Option (right to buy)	\$ 6.59						04/11/2005(6)	04/11/2015	Common Stock	1
Non-Qualified Stock Option (right to buy)	\$ 7.15						03/01/2006(7)	03/01/2016	Common Stock	4

# **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	Director 10% Owner Officer						
MORGANS DAVID J JR								
280 EAST GRAND AVENUE			SVP-Drug Discovery and Dev					
SOUTH SAN FRANCISCO, CA 94080								

Reporting Owners 2

## **Signatures**

David J. Morgans, Jr., Ph.D.

01/17/2007

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2005.
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2005.
- (3) This option is immediately exercisable upon grant and shall vest as to 833 shares on 04/15/02 and the balance of 49,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/15/07.
- (4) This option is immediately exercisable upon grant and shall vest as to 1,135 shares on 04/01/03 and the balance of 53,365 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/07.
- (5) This option shall vest and become exercisable as to 708 shares on 04/08/04 and the balance of 33,292 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/08/08.
- When the ISO and NQ dated 04/11/05 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 50,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2009.
- (7) When the ISO and NQ dated 03/01/2006 are combined for a total grant of 60,000 shares, the option shall vest and become exercisable as to 60,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3